Terumo Corp (4543 JP): Starts FY27 on Strong Note; FY Profit Guidance Revision on Tariff Refund
Terumo posted strong Q1FY27 result, with record high quarterly revenue, operating profit, and net profit. The company witnesses strong global...
89 Views
APAC Healthcare Weekly (Oct 11) – Shionogi, Terumo, Ono Pharma, Celltrion, Hanmi Pharm, CSL
Shionogi is acquiring IntraBio for $2B. Ono stuck inlicensing deal with Biohaven. Hanmi’s obesity drug got approval in Korea. CSL terminates supply...
86 Views
EQD | Long Nifty 50 Vs. Short Nikkei 225 - A Relative Value Option Strategy with a Kicker
Option strategy: exploit relative value in implied volatilities combined with directional positioning for a leveraged payoff in a long Nifty 50 vs....
865 Views
APAC Healthcare Weekly (Oct 4) – Hengrui, Hansoh, Chugai Pharma, Daiichi Sankyo, Otsuka, Sun Pharma
Hengrui stuck $2.6B outlicensing deal with Novo. EC revoked EU marketing authorization of Hansoh’s aumolertinib. Otsuka initiates NDA submission to...
97 Views
Primer: Terumo Corp (4543 JP) - Aug 2026
Terumo achieved a record-high revenue of ¥1,132B in FY26, showcasing robust growth driven by its Cardiac and Vascular (C&V) and Blood and...
101 Views